- Home
- SLN vs PLX Comparison
SLN vs PLX Comparison
Compare SLN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- PLX
- Stock Information
- Founded
- SLN 1994
- PLX 1993
- Country
- SLN United Kingdom
- PLX United States
- Employees
- SLN N/A
- PLX N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLN Health Care
- PLX Health Care
- Exchange
- SLN Nasdaq
- PLX Nasdaq
- Market Cap
- SLN 165.3M
- PLX 160.2M
- IPO Year
- SLN N/A
- PLX 1998
- Fundamental
- Price
- SLN $3.70
- PLX $1.73
- Analyst Decision
- SLN Buy
- PLX Strong Buy
- Analyst Count
- SLN 5
- PLX 1
- Target Price
- SLN $32.60
- PLX $15.00
- AVG Volume (30 Days)
- SLN 256.3K
- PLX 1.0M
- Earning Date
- SLN 05-08-2025
- PLX 05-09-2025
- Dividend Yield
- SLN N/A
- PLX N/A
- EPS Growth
- SLN N/A
- PLX N/A
- EPS
- SLN N/A
- PLX 0.04
- Revenue
- SLN $27,701,000.00
- PLX $59,764,000.00
- Revenue This Year
- SLN N/A
- PLX $65.02
- Revenue Next Year
- SLN N/A
- PLX $57.34
- P/E Ratio
- SLN N/A
- PLX $40.01
- Revenue Growth
- SLN N/A
- PLX 0.18
- 52 Week Low
- SLN $1.97
- PLX $0.82
- 52 Week High
- SLN $24.38
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SLN 55.23
- PLX 27.30
- Support Level
- SLN $3.54
- PLX $2.70
- Resistance Level
- SLN $4.15
- PLX $2.93
- Average True Range (ATR)
- SLN 0.33
- PLX 0.21
- MACD
- SLN 0.06
- PLX -0.08
- Stochastic Oscillator
- SLN 53.62
- PLX 0.36
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.